FOLLOWUS
1. Department of Cardiology, Guang’anmen Hospital,Beijing,China
2. Academy of Chinese Medical Sciences,Beijing,China
纸质出版日期:2014,
网络出版日期:2013-8-5,
Scan for full text
Wang, J., Yu, G. Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches., Chin. J. Integr. Med. 20, 163–169 (2014). https://doi.org/10.1007/s11655-013-1461-3
Jie Wang, Gui Yu. Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches[J]. Chinese Journal of Integrative Medicine, 2014,20(3):163-169.
Wang, J., Yu, G. Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches., Chin. J. Integr. Med. 20, 163–169 (2014). https://doi.org/10.1007/s11655-013-1461-3 DOI:
Jie Wang, Gui Yu. Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches[J]. Chinese Journal of Integrative Medicine, 2014,20(3):163-169. DOI: 10.1007/s11655-013-1461-3.
The prevalence of coronary heart disease (CHD) is increasing
and has been a severe burden on society and family worldwide. New ideas need to be achieved for developing more efficacious and safe therapies to treat CHD. Chinese medicine (CM) uses multicomponent drugs to prevent disease and ameliorate symptoms based on patients’ different syndromes. The benefit of CM in CHD has recently been proven by increasing clinical evidence. More importantly
linking CM syndrome differentiation and biomedical diagnosis might provide innovative thinking for treating CHD. According to epidemiological investigations
blood stasis syndrome (BSS) is the major type of syndrome in CHD. Investigating the biomedical mechanisms of BSS of CHD is a topic of CM research. Because the holistic perspective of systems biology is well matched with CM
the application of omics techniques and other integrative approaches appears inherently appropriate. A wide range of omics techniques
including transcriptomics and proteomics
have been used in studies of BSS of CHD to search for a common ground of understanding. These approaches could be useful for understanding BSS of CHD from clinical and biological viewpoints. Nevertheless
current studies mainly contain results from a single approach
and they have not achieved the holistic
systematic and integrative concept of system biology. Therefore
we discuss the progress and challenges in exploring the biomedical mechanisms of BSS of CHD by systems biology approaches. With further development of systems biology
a better platform to study BSS of CHD may be provided
and biomarkers for BSS of CHD and therapeutic targets may be found. The study of BSS of CHD by systems biology approaches will also be beneficial for developing personalized treatment for BSS of CHD patients.
The prevalence of coronary heart disease (CHD) is increasing
and has been a severe burden on society and family worldwide. New ideas need to be achieved for developing more efficacious and safe therapies to treat CHD. Chinese medicine (CM) uses multicomponent drugs to prevent disease and ameliorate symptoms based on patients’ different syndromes. The benefit of CM in CHD has recently been proven by increasing clinical evidence. More importantly
linking CM syndrome differentiation and biomedical diagnosis might provide innovative thinking for treating CHD. According to epidemiological investigations
blood stasis syndrome (BSS) is the major type of syndrome in CHD. Investigating the biomedical mechanisms of BSS of CHD is a topic of CM research. Because the holistic perspective of systems biology is well matched with CM
the application of omics techniques and other integrative approaches appears inherently appropriate. A wide range of omics techniques
including transcriptomics and proteomics
have been used in studies of BSS of CHD to search for a common ground of understanding. These approaches could be useful for understanding BSS of CHD from clinical and biological viewpoints. Nevertheless
current studies mainly contain results from a single approach
and they have not achieved the holistic
systematic and integrative concept of system biology. Therefore
we discuss the progress and challenges in exploring the biomedical mechanisms of BSS of CHD by systems biology approaches. With further development of systems biology
a better platform to study BSS of CHD may be provided
and biomarkers for BSS of CHD and therapeutic targets may be found. The study of BSS of CHD by systems biology approaches will also be beneficial for developing personalized treatment for BSS of CHD patients.
Blood Stasis Syndromecoronary heart diseasesystems biology
Blood Stasis Syndromecoronary heart diseasesystems biology
Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54–63.
Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-STElevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:e215–e367.
Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011;130:213–225.
Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011;365:2250–2251.
Andréll P, Ekre O, Grip L, Währborg P, Albertsson P, Eliasson T, et al. Fatality, morbidity and quality of life in patients with refractory angina pectoris. Int J Cardiol 2011;147:377–382.
Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol 2007;1:51–60.
Ma T, Tan C, Zhang H, Wang M, Ding W, Li S. Bridging the gap between traditional Chinese medicine and systems biology: the connection of Cold Syndrome and NEI network. Mol Biosyst 2010;6:613–619.
Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005;26:558–563.
Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–549.
Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011;17:669–674.
He QY, Wang J, Zhang YL, Tang YL, Chu FY, Xiong XJ. Effect of Yiqi Yangyin Decoction on the quality of life of patients with unstable angina pectoris. Chin J Integr Med 2010;16:13–18.
Wang J, He QY, Zhang YL. Effect of Shenshao Tablet on the quality of life for coronary heart disease patients with stable angina pectoris. Chin J Integr Med 2009;15:328–332.
Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5,284 patients with coronary artery disease: The role of integrative medicine. J Ethnopharmacol 2012;141:578–583.
Wang J, Chen KJ, Weng WL, Qian ZH, Wang Y, Liu JG, et al. Study on the diagnostic criteria of blood stasis syndrome. Chin J Integr Tradit West Med (Chin) 1988;8:585–587, 589.
Xu H, Lu XY, Chen KJ. Study on correlation of bloodstasis syndrome and its accompanied syndromes with pathological changes showed in coronary angiography and restenosis after percutaneous coronary intervention. Chin J Integr Tradit West Med (Chin) 2007;27:8–13.
Xu H, Shi DZ, Chen KJ. Clinical effect of Xiongshao capsule on preventing restenosis post-PTCA or/and stenting. Chin J Integr Tradit West Med (Chin) 2000;20:494–497.
Yang BL, Wang J, Yang J. General situation of study on blood stasis syndrome of coronary heart disease. Chin J Inf Tradit Chin Med (Chin) 2003;10:86–87.
Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001;2:343–372.
Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, et al. Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 2012;140:535–544.
Gomase VS, Tagore S. Transcriptomics. Curr Drug Metab 2008;9:245–249.
Freedman JE, Larson MG, Tanriverdi K, O’Donnell CJ, Morin K, Hakanson AS, et al. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation 2010;122:119–129.
Ma XJ, Yin HJ, Chen KJ. Differential gene expression profiles in coronary heart disease patients of blood stasis syndrome in traditional Chinese medicine and clinical role of target gene. Chin J Integr Med 2009;15:101–106.
Yang J, Wang MQ, Li WH. Correlation between blood stasis syndrome of the coronary heart disease and the abnormal expression of actin-related genes. J Tradit Chin Med (Chin) 2009;50:538–540.
Cox J, Mann M. Is proteomics the new genomics? Cell 2007;130:395–398.
Vaisar T, Mayer P, Nilsson E, Zhao XQ, Knopp R, Prazen BJ. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010;411:972–979.
Wu HJ, Ma ZC, Gao Y, Wang SQ. Study on GAP in bloodstasis type of coronary heart disease by using proteomic technique. Chin J Integr Med Cardio-/Cerebrovascular Dis (Chin) 2005;3:189–191.
Zhao HH, Wang W, Wang SR, Guo SZ, Li H. Study on unstable angina blood-stasis syndrome by two-dimensiona electrophoresis and matrix-assisted laser desorption/Ionization time of flying mass spectrometry. Chin Archives Tradit Chin Med (Chin) 2008;26:724–726.
Li XF, Jiang YR, Gao ZY. Screening, identification and analysis of platelet differential functional proteins in patients with coronary heart disease of blood-stasis pattern. Chin J Integr Tradit West Med (Chin) 2010;30:467–473.
Barton RH. A decade of advances in metabonomics. Expert Opin Drug Metab Toxicol 2011;7:129–136.
Yan B, A J, Hao H, Wang G, Zhu X, Zha W, et al. Metabonomic phenotype and identification of “heart blood stasis obstruction pattern” and “qi and yin deficiency pattern” of myocardial ischemia rat models. Sci China C Life Sci 2009;52:1081–1090.
Duncan H. An update on the clinical laboratory improvement amendments of 1988. Lab Medicine 2008;39:69–72.
0
浏览量
723
Downloads
13
CSCD
关联资源
相关文章
相关作者
相关机构